These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33931939)

  • 21. A review of excision repair cross-complementation group 1 in colorectal cancer.
    Bohanes P; Labonte MJ; Lenz HJ
    Clin Colorectal Cancer; 2011 Sep; 10(3):157-64. PubMed ID: 21855036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
    Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
    Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. XRCC2-Deficient Cells are Highly Sensitive to 5-Fluorouracil in Colorectal Cancer.
    Zhang YZ; An JH; Liu YX; Wu XC; Han SS; Ren XQ; Qin CJ
    Cell Physiol Biochem; 2017; 43(3):1207-1219. PubMed ID: 28977800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biological and predictive role of ERCC1 polymorphisms in cancer.
    Formica V; Doldo E; Antonetti FR; Nardecchia A; Ferroni P; Riondino S; Morelli C; Arkenau HT; Guadagni F; Orlandi A; Roselli M
    Crit Rev Oncol Hematol; 2017 Mar; 111():133-143. PubMed ID: 28259288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.
    Wei W; Ma XD; Jiang GM; Shi B; Zhong W; Sun CL; Zhao L; Hou YJ; Wang H
    Oncol Res; 2020 Sep; 28(4):423-438. PubMed ID: 32331534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA TUG1 promotes the progression of colorectal cancer via the miR-138-5p/ZEB2 axis.
    Yan Z; Bi M; Zhang Q; Song Y; Hong S
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32391554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ERCC1 and clinical resistance to platinum-based therapy.
    Reed E
    Clin Cancer Res; 2005 Sep; 11(17):6100-2. PubMed ID: 16144907
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
    Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer.
    Dutton SJ; Kenealy N; Love SB; Wasan HS; Sharma RA;
    BMC Cancer; 2014 Jul; 14():497. PubMed ID: 25011439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZEB2-AS1 Accelerates Epithelial/Mesenchymal Transition Through miR-1205/CRKL Pathway in Colorectal Cancer.
    Jiang Y; Liu G; Ye W; Xie J; Shao C; Wang X; Li X
    Cancer Biother Radiopharm; 2020 Mar; 35(2):153-162. PubMed ID: 31755734
    [No Abstract]   [Full Text] [Related]  

  • 38. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
    Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
    Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ERCC5 promoter polymorphisms at -763 and +25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer.
    Chen J; Xie F; Chen K; Wang D; Jiang H; Li J; Pan F; Chen S; Zhang Y; Ruan Z; Huang H; Zou L; Liang H
    Cancer Biol Ther; 2009 Jul; 8(14):1424-30. PubMed ID: 19458483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.
    Sreekumar R; Harris S; Moutasim K; DeMateos R; Patel A; Emo K; White S; Yagci T; Tulchinsky E; Thomas G; Primrose JN; Sayan AE; Mirnezami AH
    JAMA Netw Open; 2018 Oct; 1(6):e183115. PubMed ID: 30646224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.